

Oncolytics Biotech

Promising lung cancer data

Promising tumour response data from two Phase II studies of Reolysin in squamous cell carcinoma of the lung (SCC lung) and in non-small cell lung cancer (NSCLC) support further randomised trials in these indications. Oncolytics has an ongoing Phase II trial in SCC and adenocarcinoma of the lung. Data from the lead Phase II squamous cell head and neck cancer trial are expected soon.

Year end	Revenue (C\$m)	PBT* (C\$m)	EPS* (c)	DPS (c)	P/E (x)	Yield (%)
12/11	0.0	(28.3)	(39.9)	0.0	N/A	N/A
12/12	0.0	(36.3)	(47.3)	0.0	N/A	N/A
12/13e	0.0	(37.2)	(43.9)	0.0	N/A	N/A
12/14e	0.0	(36.3)	(42.2)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

Positive Phase II lung cancer data

Results from a single-arm Phase II trial (REO 021) in metastatic stage IIIB or stage IV, or recurrent chemotherapy-naïve SCC lung patients treated with Reolysin in combination with carboplatin and paclitaxel demonstrated that of the 25 evaluable patients, 23 (92%) exhibited overall tumour shrinkage (mean shrinkage was 32.7%); 10 (40%) had partial responses (PRs), 13 (52%) showed stable disease (SD) and two (8%) had progressive disease (PD), for a disease control rate [DCR] (complete response [CR] + PR + SD) of 92%. Final results from a single-arm Phase II trial (REO 016) in metastatic NSCLC patients with a Ras-activated pathway treated with Reolysin in combination with carboplatin and paclitaxel showed that of the 37 evaluable patients, 11 (30%) had PRs, 21 (57%) SD and four (11%) PD for a DCR of 89%. To date, six-month PFS was 36% and one-year survival was 53%.

More active in metastatic head and neck cancer

Preliminary data from the REO 018 Phase III trial in squamous cell carcinoma of the head and neck (SCCHN) suggested that Reolysin in combination with carboplatin and paclitaxel was more active in metastatic than in loco-regional disease. The trial has been restructured to provide data for the basis for a future pivotal study in metastatic SCCHN; these data are expected soon.

Financials: Funded to H214

Following a capital raising of around US\$32m (gross) in February, Oncolytics ended Q2 with cash of C\$38.2m, which should provide a cash runway into H214.

Valuation: Risk-adjusted NPV of C\$457m

Our rNPV has increased to C\$457m following the recent positive SCC lung and NSCLC data. This is based on prudent assumptions of Reolysin's probability of success in each indication, launch date, pricing and market penetration. By comparison, Oncolytics's EV is currently C\$174m, based on a market cap of C\$212m and end-Q2 cash of C\$38.2m.

Update: SCC lung data

Pharma & biotech

3 October 2013

Price **C\$2.50**
Market cap **C\$212m**

Net cash (C\$m) at end June 2013	38.2
Shares in issue	84.8m
Free float	98%
Code	ONC
Primary exchange	TSX
Secondary exchange	NASDAQ

Share price performance



%	1m	3m	12m
Abs	(10.7)	(17.2)	7.8
Rel (local)	(11.6)	(21.5)	3.8
52-week high/low		C\$4.8	C\$1.7

Business description

Oncolytics Biotech is a Canadian company focused on developing Reolysin, a pharmaceutical formulation of the oncolytic reovirus, for the treatment of a wide variety of human cancers (Phase III trial in head and neck cancer).

Next events

SCCHN data	Q413
Pancreatic Phase II data	Q413

Analysts

Dr Wang Chong	+44 (0)20 3077 5700
Robin Davison	+44 (0)20 3077 5737

healthcare@edisongroup.com

[Edison profile page](#)

Oncolytics datasheet

Exhibit 1: Reolysin clinical studies underway

Code	Indication	Trial design	Notes
REO 018	Squamous cell carcinoma of the head and neck (SCCHN)	160-pt Phase III trial of carboplatin/paclitaxel ± Reolysin in platinum-refractory metastatic/recurrent SCCHN. First stage segregated into two groups: local ± mets and distal mets.	Primary: OS. Secondary: PFS, S&T. Reolysin + carbo-tax shown to be significantly better than control in stabilising or shrinking metastatic tumours (p=0.03) (results: H213).
IND211 (NCIC-CTG)	Non-small cell lung cancer (NSCLC)	150-pt Phase II study of pemetrexed ± Reolysin (squamous) or docetaxel ± Reolysin (adeno).	Primary: PFS. Secondary: AE, RR (PR, ORR, OS), molecular factors (results: Q414).
IND213 (NCIC-CTG)	Metastatic breast cancer	100-pt Phase II trial of Reolysin ± paclitaxel.	Primary: PFS. Secondary: ORR, OS, molecular factors (results: Q414).
IND210 (NCIC-CTG)	Metastatic colorectal cancer	100-pt Phase II trial of FOLFOX6 and bevacizumab ± Reolysin.	Primary: PFS. Secondary: CEA, ORR, OS, molecular factors and QoL (results: Q214).
REO 022		12-20-pt Phase I trial of Reolysin with FOLFIRI (three doses, each with 3-6 pts) in oxaliplatin-refractory or intolerant KRAS mutants.	Primary: MTD and DLT. Secondary: ORR, CBR, PFS, OS, and safety and tolerability (results: TBA).
NCIC-CTG Study	Metastatic CRPC	80-pt Phase II trial of docetaxel/prednisone ± Reolysin.	Primary: disease progression. Secondary: circulating tumour cells, PSA and OS (results: Q414).
OSU-10045 (NCI)	Metastatic pancreatic cancer	70-pt open-label Phase II study of carboplatin/paclitaxel ± Reolysin (first-line rec/met).	Primary: PFS. Secondary: ORR and OS (results: H114).
GOG-0186H (NCI)	Ovarian cancer	45-pt open-label Phase II trial of Reolysin given IV and intraperitoneally (IP).	Primary: S&T, MTD of IP Reolysin when used with IV Reolysin and ORR (results: N/A).
GOG-0186H		150-pt open-label Phase II study of carboplatin/paclitaxel ± Reolysin.	Primary: PFS and AEs. Secondary: PFS and OS, tumour response by RECIST (results: H213).
REO12	Solid tumours	36-pt open-label study of Reolysin + cyclophosphamide (incl pancreatic, lung, ovarian).	Primary: MED. Secondary: safety, anti-tumour activity.
COG-ADVL1014 (NCI/COG)		45-pt Phase I study of Reolysin + cyclophosphamide in paediatric pts.	Primary: MTD, Phase II dose, AEs. Secondary: PK, anti-tumour activity, neutralising antibodies (results: Q414).
OSU-11148 (NCI)	Multiple myeloma	12-pt Phase I open-label dose escalation study of Reolysin in relapsed MM.	Primary: AEs, MTD, ORR. Secondary: PFS, duration of response and TTP (results: Q114).

Source: Edison Investment Research

Exhibit 2: Selected completed Reolysin study results (Phase I/II or II only)

Code	Indication	Notes
REO 021	SCC lung	36-pt open-label Phase II trial of Reolysin + paclitaxel/carboplatin in metastatic or recurrent squamous, chemo-naïve. Primary: ORR. Secondary: PFS and OS. First stage: 5 (of 15) PR + 8 SD = 87% DCR. Second stage: met primary end point after 21 (of 36) pts; 9 PR, 9SD, ORR: 42.8%, DCR: 85.7%. Of 25 evaluable pts: 23 (92%) exhibited overall tumour shrinkage (mean shrinkage: 32.7%); 10 (40%) PR, 13 (52%) SD and 2 (8%) PD = 23 DCR (92%).
REO 016	NSCLC	37-pt open-label Phase II trial with paclitaxel and carboplatin in metastatic or recurrent NSCLC with KRAS or EGFR-activated tumours. Primary: ORR and PFS6. Secondary: median OS, PFS and OS at one year, and safety and tolerability. Interim data on 20 pts show 6 PRs (30%), 12 SD (60%), 2 PD (10%) for CBR of 90% and ORR of 30%. Final data in 37 pts: 11 PR (30%), 21 SD (57%), 4PD (11%) = 89% DCR. To date, 6-month PFS 36% and 1-year survival 53%.
REO 020	Metastatic melanoma	43-pt open-label Phase II trial of Reolysin + carboplatin/paclitaxel. Primary: ORR. Secondary: PFS, OS, DCR and duration and S&T. First stage: 14 (of 18): 3 PR, 7 SD, ORR: 21.4%, DCR: 71.5%. Met primary end point, but not proceeding to second stage because of changing treatment landscape. Reolysin to be re-evaluated with new immunotherapies.
REO 017	Pancreatic cancer	33-pt open-label Phase II study of Reolysin + gemcitabine. Primary end point met in Dec 2011 with 8/13 evaluable pts in SD≥12 wks; ORR: 62%, CBR of 62%.
REO 015	SCCHN	14-pt open-label Phase II trial of Reolysin with paclitaxel/carboplatin. All 14 pts had received previous chemotherapy and/or radiotherapy; 10 had received previous taxane treatment. Of the 13 pts evaluable for response, 4 PRs; ORR of 31%. 6 SD>12 wks, DCR of 46%. 2 of the 4 PRs and both SD patients had received previous treatment with taxanes.
REO 014	Sarcoma	53-pt Phase II study (completed in November 2009) demonstrated positive results.
REO 013	mCRC	10-pt open-label study of IV Reolysin before surgical resection of colorectal liver metastases. Primary objectives are to assess the presence, replication and anticancer effects of reovirus within liver metastases by examination of the resected tumour. Early results reported in 2010 concluded that the reovirus could be delivered successfully specifically to colorectal liver metastases.

Source: Edison Investment Research


Update: Positive Phase II lung cancer data

Promising tumour response data from the (REO 021) Phase II trial in squamous cell carcinoma of the lung (SCC lung) and the (REO 016) Phase II trial in NSCLC support further randomised trials in these indications. Meanwhile, an ongoing NCIC Phase II trial in SCC and adenocarcinoma of the lung is enrolling patients. Preliminary data from the REO 018 Phase III squamous cell carcinoma of the head and neck (SCCHN) trial suggested that Reolysin in combination with carboplatin and paclitaxel is more active in metastatic than in loco-regional disease. The trial has been restructured to provide data for the basis for a future pivotal study in metastatic SCCHN; these data are expected soon.

Positive Phase II SCC lung and NSCLC data

Final results from a single-arm Phase II trial (REO 021) in metastatic stage IIIB or stage IV, or recurrent chemotherapy-naïve SCC lung patients treated with Reolysin in combination with carboplatin and paclitaxel demonstrated that of the 25 evaluable patients, 23 (92%) exhibited overall tumour shrinkage (mean shrinkage was 32.7%); 10 (40%) had PRs, 13 (52%) showed SD and two (8%) had PD for a disease control rate [DCR] (CR + PR + SD) of 92%. Oncolytics had previously announced that the trial had reached its primary endpoint in March. A waterfall plot is shown in Exhibit 3 below. Final progression-free survival (PFS) and safety data will be reported later in 2013. Oncolytics is now planning to conduct randomised clinical trials for SCC lung.

Exhibit 3: REO-021: Best overall percentage response in target lesions (final data)



Source: Oncolytics Biotech

Final results from a single-arm Phase II trial (REO 016) in metastatic or recurrent NSCLC patients with a Ras-activated pathway treated with Reolysin in combination with carboplatin and paclitaxel demonstrated that of the 37 evaluable patients (20 Kras, three EGFR, four BRAF mutations and 10 EGFR amplifications), 11 (30%) had PR (five EGFR amplified, two BRAF, three Kras and one EGFR mutated), 21 (57%) showed SD and four (11%) had PD, for a DCR of 89%. To date, PFS at six months was 36% and one-year survival was 53%. These results compare favourably with reported one-year survival rates of various chemotherapy combination treatments averaging 33% in advanced and 16% in Stage IV NSCLC patients.

Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer and can be divided into adenocarcinoma (35-40%), squamous cell (25-30%) and large cell anaplastic (10-15%). Incidence of NSCLC is around 0.06% of the population, approximately 215,000 Americans with an estimated 161,000 deaths, see Exhibit 4 for details. NSCLC is only moderately chemosensitive, but chemotherapy is used in addition to surgery and radiotherapy to treat cancer that has spread to the lymph nodes. The standard chemotherapy regimen includes cisplatin/carboplatin, which can also be used pre-operatively.

Exhibit 4: Non-small cell lung cancer background

What is non-small cell lung cancer?	Lung cancer is the commonest cause of cancer related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers and can be divided into: adenocarcinoma (35-40%), squamous cell carcinoma [SCC lung] (25-30%) and large cell carcinoma (10-15%). The commonest cause is smoking (80-90%). Other causes include: genetic factors (<i>ras</i> , <i>c-myc</i> , <i>c-raf</i> oncogenes, <i>p53</i> tumour suppressor gene), radon gas, asbestos, arsenic, chromium, nickel and air pollution.
Incidence	US (2009): 64.3 per 100,000 or 215,000 cases and 161,000 deaths UK (2009): 49.7 per 100,000 or 41,428 cases
Staging	Based on TNM classification: Tumour (0-4), Node (0-3), Metastasis (0-1). Nearly 70% of patients have locally advanced or metastatic disease at diagnosis.
Symptoms	NSCLC is often insidious; there may be no symptoms until the disease is well-advanced. At initial diagnosis, 20% of patients have localised disease, 25% have regional metastasis and 55% have distant spread of disease. Common symptoms include: cough, chest pain, shortness of breath, coughing up blood, wheezing, hoarseness, recurrent chest infections, weight loss, anorexia and fatigue. Metastatic symptoms include: bone pain, spinal cord compression and neurological symptoms.
Diagnosis	<ul style="list-style-type: none"> ■ Chest X-ray, CT scan, PET scan ■ Bronchoscopy and biopsy, sputum cytology, thoracoscopy, transthoracic needle biopsy.
Treatment	<p>Treatments include:</p> <ul style="list-style-type: none"> ■ Surgery: treatment of choice for Stage I and II. Types include: lobectomy, pneumonectomy and wedge resection. ■ Chemotherapy: 80% receive chemotherapy. First-line treatment should include a platinum (cis/carboplatin). Combinations include: cisplatin-gemcitabine, cisplatin-paclitaxel, cisplatin-docetaxel, and carboplatin-paclitaxel, suggested similar overall response rates (approximately 19%), and median survival (7.9 months). One- and two-year overall survival was also similar at 33% and 11%, respectively. ■ Biologicals: bevacizumab, cetuximab and tyrosine kinase inhibitors: afatinib, gefitinib, erlotinib, crizotinib. ■ Radiotherapy
Prognosis	Five-year survival rate: US: 15.7%, EU: 8%. Depends on how advanced at diagnosis: local: 49%, regional: 16%, metastases: 2%. By stage: IA: 75%, IB: 55%, IIA: 50%, IIB: 40%, IIIA: 10-35%, IIIB: <5%, IV: <5%.

Source: Edison Investment Research

Chemotherapy combinations including cisplatin/carboplatin with vinorelbine, gemcitabine, paclitaxel/docetaxel and pemetrexed can double the response rate but toxicity is also higher. Erbitux (cetuximab) is thought to act synergistically with cis/carboplatin, paclitaxel and vinorelbine in EGFR mutant patients but toxicity can be high. Bevacizumab (Avastin) can be used in non-squamous patients. Other EGFR inhibitors are gefitinib (Iressa) and erlotinib (Tarceva). There are numerous products in Phase III trials for NSCLC including mAbs, targeted therapies such as Giotrif¹ (afatinib, Boehringer Ingelheim), immunotherapies and vaccines such as tecemotide (Merck KGaA/Oncocyte). However, there are relatively few products in Phase III trials for SCC lung; see Exhibit 5 for details. The unmet medical need remains high. Patients with squamous cell carcinoma represent about 30% of all patients affected by NSCLC and has a poorer prognosis compared to non-squamous.

Exhibit 5: Products in Phase III trials for SCC lung

Product	Company	Notes
Gilotrif (afatinib)	Boehringer Ingelheim	800-pt Phase III randomised, open-label trial of afatinib versus erlotinib in advanced SCC lung as second-line therapy following first-line platinum-based chemotherapy. Results: Q413.
Ipilimumab	BMS	920-pt Phase III randomised, multicentre, double-blind, trial comparing efficacy of ipilimumab/paclitaxel/carboplatin versus placebo/paclitaxel/carboplatin in stage IV/recurrent NSCLC. Results: Q215.
TG4010	Transgene	1,000-pt randomised, double-blind Phase IIB/III study comparing first-line therapy with or without TG4010 immunotherapy stage IV NSCLC (squamous and non-squamous). Results: Q116.

Source: Edison Investment Research

Lilly recently obtained a positive Phase III result in its SQUIRE study of necitumumab as a first-line treatment of stage IV metastatic squamous NSCLC in combination with gemcitabine plus cisplatin. The study showed an increase in OS when given IMC-11F8 in combination with chemotherapy, as compared to chemotherapy alone. If approved, necitumumab would be the first biologic therapy indicated to treat patients with squamous lung cancer.

Several randomised controlled trials have failed to show a clear superiority of one platinum-containing combination over another. A landmark ECOG trial comparing cisplatin-gemcitabine, cisplatin-paclitaxel, cisplatin-docetaxel and carboplatin-paclitaxel suggested similar ORRs (around 19%) and median survival (7.9 months); one and two-year overall survival (OS) were also similar at 33% and 11% respectively. A meta-analysis comparing cisplatin-gemcitabine with other platinum-containing regimens suggested an improved median survival (9.0 versus 8.2 months) and an

¹ Recently approved in US/EU for NSCLC with activating EGFR mutations in patients who are EGFR tyrosine kinase inhibitor-naïve.

absolute improvement in one year OS of 3.9% as compared to non-gemcitabine combinations. However, this effect was not sustained when compared against other third-generation cisplatin combinations.²

Abraxane (nab-paclitaxel, Celgene) is approved for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. Approval was based on a single-phase, multicentre, randomised open-label study. ORR was significantly higher (33% versus 25%; p=0.005). In SCC lung, the ORR was also statistically superior (41% vs 24%; p < 0.001). However, there was no statistically significant difference in OS.

Exhibit 6: Efficacy data from studies of agents in Phase III in second-line NSCLC

Compound	Study	Median PFS (test vs control)	Median OS (test vs control)
Nintedanib/ Boehringer Ingelheim	1,315-pt Phase III study (LUME-LUNG-1) of docetaxel ± nintedanib	ITT: 3.4 vs 2.7 mths, HR=0.79 (95%CI: 0.68-0.92, p=0.0019). Adenocarcinoma: 4.0 vs 2.8 mths, HR=0.77, (95%CI: 0.62-0.96, p=0.0193). Squamous: 2.9 vs 2.2 mths, HR= 0.77 (0.62 to 0.96), p=0.0200.	ITT: 10.1 mths vs 9.1 mths, HR=0.94 (95% CI: 0.83-1.05, p= 0.2720). Adenocarcinoma: 12.6mths vs 10.3mths, HR=0.83 (95% CI: 0.70-0.99, p=0.0359). Squamous: 8.6 vs 8.7 mths (HR-1.01, 95% CI 0.95, 1.01, p=0.8907).
	713-pt Phase III study (LUME-Lung 2) of pemetrexed ± nintedanib	ITT: 4.4mths vs 3.6mths (HR=0.83 [95% CI: 0.7–0.99], p=0.04). DCR was significant (61% vs 53%, odds ratio 1.37, p=0.039). No difference in response rate.	No difference in OS (HR=1.03), although study was stopped early after failing interim analysis with 713 of planned 1,300 pts.
Lucanix (belagenpumat ucel-L)/ NovaRx	532-pt Phase III study in post-frontline maintenance therapy		ITT: N/S due to the inclusion of pts > 2 wks from completion of first line chemotherapy. <12 wks from completion first line therapy (n=305): 20.7 vs 13.4 mths (HR 0.75). Squamous: 20.7 vs 12.3 mths (HR 0.58). Prior radiation Tx: 40.1 vs 10.3 mths (HR 0.45).
Dacomitinib/ Pfizer	188-pt Phase II trial of dacomitinib vs erlotinib	ITT: 2.86mths vs 1.91 mths (HR=0.66; 95%CI 0.47-0.91; p=0.012). K-ras wt: 3.71 mths vs 1.91 mths (HR=0.55; 95%CI 0.35-0.85; p=0.006). K-ras wt/EGFR wt: 2.21 mths vs 1.84 mths (HR=0.61; 95%CI 0.37-0.99; p=0.043).	ITT: 9.53 vs 7.44 mths (HR=0.80; 95%CI 0.56-1.13; p=0.205).
Onartuzumab/ Roche	128-pt Phase II study of erlotinib ± onartuzumab (second/third-line)	ITT: 2.2 mths vs. 2.6 mths, NS (HR=1.09, p=0.687). Met high: 2.9 mths vs 1.5 mths (HR=0.53; p=0.04). Met low: 1.4 mths vs. 2.7 mths (HR=1.82, p=0.050)	ITT: N/A (presumably NS). Met high: 12.6 mths vs 3.8 mths (HR=0.37; p=0.002). Met low: 8.1 mths vs. 15.3 mths (HR=1.78, p=0.158)
Bavituximab/ Peregrine	121-pt Phase II study of docetaxel ± bavituximab	Active (n=41, 3mg/kg) vs control* (n=80, pooled pbo + 1mg/kg B). 4.5 vs 3.3 mths.	11.7 vs 7.3 mths for control.* (HR=0.73; p=0.217).
Selumetinib/ AZ/Array	87-pt Phase II study of docetaxel ± selumetinib in K-ras mt	5.3 vs 2.1 mths (HR=0.58; 80%CI 0.42-0.79; p=0.0138).	9.4 vs 5.2 mths (HR=0.80; 80%CI 0.56-1.14; p=0.2069).

Source: Edison Investment Research. Note: Excludes studies in squamous and ALK+ only. *Control represents 1mg/kg and placebo, which were pooled as a result of labelling errors.

Sensitivities

Oncolytics is exposed to typical biotech company development risks, including the unpredictable outcome of trials, as highlighted in last year's outcome of the SCCHN study. It has a very high single-product risk, with the entirety of its value residing in Reolysin. The investment case hinges on Oncolytics's ability to secure a licensing deal to commercialise Reolysin and fund the pivotal Phase III trials required in larger indications such as NSCLC and CRC. Ideally, such a partner would have an established oncology franchise so that it can provide the resources and experience to conduct trials in multiple indications to fully exploit the novel technology. A licensing deal should achieve a significant re-rating in valuation.

² Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. Jan 2005; 47(1): 69-80.

Valuation

Our risk-adjusted valuation has increased to C\$457m following the impact of the recent positive SCC lung and NSCLC data on our risk-adjustment; the probability of success has been increased from 30% to 40%. This valuation compares to a current EV of C\$176m, based on a market cap of C\$214m and an end-Q2 cash of C\$38.2m. This valuation model is based on what Edison believes to be prudent assumptions of probability of success, launch date, pricing and market penetration in each indication. The probabilities of success in the different indications are in line with industry norms. No upfront or milestone payments from a licensing partner have been assumed in our model. For simplicity, our valuation model assumes a Reolysin price of C\$20,000 per course of treatment across all the indications considered; however, higher pricing may be possible.

Financials

Following a capital raising of around US\$32m (gross) in February, Oncolytics ended Q2 with cash of C\$38.2m, which should provide a cash runway into H214. For the capital raising, 8.0m ordinary shares were issued at US\$4.00 per share. Our forecast FY13 R&D spend has been revised to reflect fewer ongoing Oncolytics sponsored trials. However, R&D spend will be reviewed when the future of the SCCHN programme has been clarified later this year.

Exhibit 6: Financial summary

	C\$'000s	2011	2012	2013e	2014e	2015e
Year end 31 December		Can GAAP	Can GAAP	Can GAAP	Can GAAP	Can GAAP
PROFIT & LOSS						
Revenue		0	0	0	0	0
Cost of sales		0	0	0	0	0
Gross Profit		0	0	0	0	0
EBITDA		(28,684)	(36,617)	(37,448)	(36,614)	(33,474)
Operating profit (before GW and except.)		(28,725)	(36,688)	(37,521)	(36,688)	(33,548)
Intangible amortisation		(736)	0	0	0	0
Exceptionals		0	0	0	0	0
Other		39	0	0	0	0
Operating profit		(29,422)	(36,688)	(37,521)	(36,688)	(33,548)
Net interest		416	345	345	345	345
Profit before tax (norm)		(28,309)	(36,343)	(37,176)	(36,343)	(33,203)
Profit before tax (FRS 3)		(29,006)	(36,343)	(37,176)	(36,343)	(33,203)
Tax		(40)	(30)	0	0	0
Profit after tax (norm)		(28,310)	(36,313)	(37,176)	(36,343)	(33,203)
Profit after tax (FRS 3)		(29,046)	(36,374)	(37,176)	(36,343)	(33,203)
Average number of shares outstanding (m)		70.9	76.7	84.8	86.1	88.1
EPS – normalised (c)		(39.9)	(47.3)	(43.9)	(42.2)	(37.7)
EPS – FRS 3 (c)		(41.0)	(47.4)	(43.9)	(42.2)	(37.7)
Dividend per share (c)		0.0	0.0	0.0	0.0	0.0
BALANCE SHEET						
Fixed assets		392	409	409	409	409
Intangible assets		0	0	0	0	0
Tangible assets		392	409	409	409	409
Investments		0	0	0	0	0
Current assets		35,633	21,669	16,662	3,686	3,483
Stocks		0	0	0	0	0
Debtors		55	45	48	51	55
Cash		34,856	21,293	16,314	3,334	3,128
Current liabilities		(6,504)	(7,291)	(10,208)	(14,291)	(20,007)
Creditors		(6,504)	(7,291)	(10,208)	(14,291)	(20,007)
Short-term borrowings		0	0	0	0	0
Long-term liabilities		0	0	0	(20,000)	(48,000)
Long-term borrowings		0	0	0	(20,000)	(48,000)
Other long term liabilities		0	0	0	0	0
Net assets		29,520	14,787	6,863	(30,196)	(64,115)
CASH FLOW						
Operating cash flow		(24,451)	(36,374)	(34,534)	(32,535)	(27,761)
Net interest		(416)	(345)	(345)	(345)	(345)
Tax		0	0	0	0	0
Capex		(100)	(126)	(100)	(100)	(100)
Acquisitions/disposals		0	0	0	0	0
Financing		16,917	21,747	30,000	0	0
Dividends		0	0	0	0	0
Net cash flow		(8,050)	(15,097)	(4,979)	(32,980)	(28,206)
Opening net debt/(cash)		(42,906)	(34,856)	(21,293)	(16,314)	16,666
HP finance leases initiated		0	0	0	0	0
Other		0	1,535	0	0	0
Closing net debt/(cash)		(34,856)	(21,293)	(16,314)	16,666	44,872

Source: Company accounts, Edison Investment Research. Note: Long-term liabilities assume capital raisings for illustrative purposes.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Oncolytics Biotech and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). It is not intended for retail clients. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2013. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.